Logo

HURA

TuHURA Biosciences, Inc.

HURA

TuHURA Biosciences, Inc. • NASDAQ
$2.00 ▼ -4.31% (-0.09)
Market Cap $101.79 M
52w High $7.20
52w Low $1.56
Dividend Yield 0%
P/E -2.7
Volume 65.78K
Outstanding Shares 50.89M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $23.623M ▲ $-23.297M ▼ 0% $0 ▲ $0 ▲
Q2-2025 $0 $9.876M ▲ $-9.524M ▼ 0% $-0.214 ▼ $-9.524M ▼
Q4-2024 $0 $5.677M ▲ $-5.996M ▼ 0% $-0.142 ▲ $-5.455M ▼
Q3-2024 $0 $2.209M ▲ $-5.579K ▼ 0% $-2.999 ▼ $-2.18M ▼
Q2-2024 $0 $0 $0 0% $-1.472 $0

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $8.513M ▼ $34.621M ▲ $15.172M ▲ $19.45M ▲
Q4-2024 $12.657M ▲ $19.967M ▲ $5.373M ▲ $14.594M ▲
Q3-2024 $3.02M ▼ $4.14M ▼ $2.445M $1.695M ▼
Q2-2024 $4.909M ▲ $6.202M ▲ $2.445M ▼ $3.757M ▲
Q1-2024 $4.461M $5.786M $11.852M $-6.066M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-16.188M ▼ $-10.987M ▼ $-1.308M ▼ $8.15M ▲ $-4.144M ▼ $-11.035M ▼
Q4-2024 $-5.996M ▼ $-2.6M ▼ $-823.54K ▼ $-3.516M ▼ $0 ▲ $-2.621M ▼
Q3-2024 $-2.161M ▲ $-1.889M ▲ $0 $0 ▼ $-1.889M ▼ $-1.889M ▲
Q1-2024 $-4.842M ▼ $-3.834M ▼ $0 ▲ $4.631M ▲ $796.458K ▲ $-3.834M ▼
Q4-2023 $-1.023M $-2.117M $-20K $2.579M $0 $-2.137M

Five-Year Company Overview

Income Statement

Income Statement TuHURA is still a pure research-stage biotech, so it has no product revenue at all in the period shown. All activity runs through operating expenses, mainly research and development and overhead. The company has reported steady losses each year, which is typical for a clinical‑stage biotech that has not yet commercialized a drug. Per‑share loss figures look extreme largely because of repeated reverse stock splits, which mechanically amplify the loss per share without changing the underlying business performance. Overall, the income statement reflects a company fully in investment mode, not yet in a commercial phase.

Balance Sheet

Balance Sheet The balance sheet is very light, with only a small base of assets, made up largely of cash. There is essentially no financial debt, which simplifies the capital structure but also highlights how dependent the company is on new equity or similar financing to continue operations. Shareholders’ equity is positive but thin, indicating only a modest financial cushion. In simple terms, TuHURA has a clean but fragile balance sheet: little leverage, but also limited resources and a need for ongoing access to capital.

Cash Flow

Cash Flow Cash flows show a consistent pattern of money flowing out of the business to fund operations and clinical development, with no offsetting inflow from product sales. Operating cash flow has been negative each year, and free cash flow mirrors this because the company is not investing heavily in physical assets or equipment. This means most cash use is tied directly to people, trials, and research. The business model is therefore heavily reliant on periodic capital raises. The core question going forward is how effectively the company can match its cash burn with future financing and any potential partnering income.

Competitive Edge

Competitive Edge TuHURA occupies a focused niche in immuno‑oncology, aiming to solve the problem of resistance to existing cancer immunotherapies. Its competitive strength comes from three distinct but complementary platforms: an in‑tumor vaccine approach (IFx), a novel immune checkpoint target (VISTA), and a strategy to reprogram the tumor microenvironment via the delta opioid receptor on suppressive immune cells. These mechanisms are differentiated from many mainstream checkpoint and cell therapy approaches and target patient groups with high unmet need, which could support premium positioning if successful. On the other hand, the company is small and faces intense competition from far larger, well‑funded players in cancer immunotherapy. Its competitive standing will depend heavily on clinical data quality, speed of execution, and its ability to secure partnerships or alliances to support commercialization.

Innovation and R&D

Innovation and R&D Innovation is clearly TuHURA’s core asset. The IFx platform seeks to turn a patient’s own tumor into a personalized vaccine, which is a novel twist on in‑situ immunotherapy. The VISTA antibody program (TBS‑2025), added through acquisition, extends the company into a next‑generation checkpoint space focused on myeloid cells rather than just T‑cells. The delta opioid receptor work pushes further into reprogramming the tumor microenvironment using advanced antibody‑drug designs. Together, these platforms give TuHURA multiple shots on goal, including a late‑stage trial in a rare skin cancer and earlier‑stage programs in blood cancers and preclinical assets. However, the R&D strategy is high risk by nature: scientific and regulatory uncertainty is substantial, timelines are long, and progress turns on delivering convincing human data and managing trial complexity with limited resources.

Summary

Overall, TuHURA is a classic early‑ to mid‑stage biotech profile: no revenue, recurring losses, and a very lean balance sheet, but anchored by a distinctive and science‑heavy pipeline in immuno‑oncology. Financially, the company lives on external funding, with ongoing cash burn and no near‑term prospect of operating self‑sufficiency. Strategically, its value proposition rests on the success of a few key clinical milestones, particularly the pivotal trial for IFx‑2.0 and the advancement of the VISTA and DOR platforms. The opportunity lies in the potential for first‑in‑class or best‑in‑class therapies in areas of high unmet medical need; the main risks are clinical failure, delays, financing constraints, and dilution, all in a very competitive cancer‑drug landscape. Anyone following the company would likely focus on trial readouts, regulatory interactions, partnership activity, and the pace of cash usage as the critical markers of how the story is unfolding.

NEWS

November 14, 2025 · 7:00 AM UTC

TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Read more

November 3, 2025 · 9:01 AM UTC

TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition

Read more